Get your Morning Sixpack here

6 news stories every business day

Ridgeback Biotherapeutics and Drug Innovations Ventures at Emory Partner to Develop Clinical Stage Coronavirus Treatment

Ridgeback Biotherapeutics and Drug Innovations Ventures at Emory Partner to Develop Clinical Stage Coronavirus Treatment 1

ATLANTA and MIAMI, March 19, 2020 /PRNewswire/ — Ridgeback Biotherapeutics LP, a closely held biotechnology company, and Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University, today announced a collaboration to rapidly advance DRIVE's EIDD-2801, a promising oral COVID-19 treatment, into human testing. This collaboration combines Ridgeback's unique experience advancing drug development efforts in the midst of an on-going disease outbreak with the three decades of experience that the DRIVE executive team has in antiviral drug development and commercialization.

Source: Ridgeback Biotherapeutics and Drug Innovations Ventures at Emory Partner to Develop Clinical Stage Coronavirus Treatment


{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

Morning Sixpack Archive

Recent Posts

>